Showing results (31-40 of 133) with videos related to

Sort By:
Pageof 14
Vaccine|January 12, 2013
13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trialSven Arne Silfverdal, Carl-Erik Flodmark, Lars Rombo, et al.
Bioorganic & Medicinal Chemistry Letters|August 25, 2004
P1' oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1Ronald M Kim, Elizabeth A Rouse, Kevin T Chapman, et al.
Plos Pathogens|May 14, 2009
Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titersAnn J Hessell, Eva G Rakasz, Pascal Poignard, et al.
The Pediatric Infectious Disease Journal|October 1, 2011
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in CanadaOtto G Vanderkooi, David W Scheifele, Douglas Girgenti, et al.
Vaccine|May 22, 2013
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adultsLisa A Jackson, Alejandra Gurtman, Martin van Cleeff, et al.
Vaccine|March 11, 2014
Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of ageRichard N Greenberg, Alejandra Gurtman, Robert W Frenck, et al.
AIDS (London, England)|April 19, 2015
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccinationAs'ad E Bhorat, Shabir A Madhi, France Laudat, et al.
Vaccine|April 27, 2010
Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in GermanyDorothee M Kieninger, Kathrin Kueper, Katrin Steul, et al.
Vaccine|May 22, 2013
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccineLisa A Jackson, Alejandra Gurtman, Kathryn Rice, et al.
The Pediatric Infectious Disease Journal|October 30, 2012
Antibody responses to routine pediatric vaccines administered with 13-valent pneumococcal conjugate vaccineKristina A Bryant, Alejandra Gurtman, Douglas Girgenti, et al.
Pageof 14